Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation.

Ellen Hubin  
*University of Twente*

Philip B Verghese  
*Washington University School of Medicine in St. Louis*

Nico van Nuland  
*Vrije Universiteit Brussel (VUB)*

Kerensa Broersen  
*University of Twente*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Please let us know how this document benefits you.

**Recommended Citation**

Hubin, Ellen; Verghese, Philip B; van Nuland, Nico; and Broersen, Kerensa, "Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation." FEBS letters. 593, 11. 1144 - 1153. (2019).

[https://digitalcommons.wustl.edu/open_access_pubs/11801](https://digitalcommons.wustl.edu/open_access_pubs/11801)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation

Ellen Hubin¹,²,³, Philip B. Verghese⁴, Nico van Nuland²,³ and Kerensa Broersen¹,⁵,†

¹ Nanobiophysics Group, Technical Medical Centre, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands
² Structural Biology Brussels, Department of Biotechnology (DBIT), Vrije Universiteit Brussel (VUB), Belgium
³ Structural Biology Research Center, VIB, Brussels, Belgium
⁴ Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
⁵ Applied Stem Cell Technologies, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands

Correspondence
K. Broersen, Applied Stem Cell Technologies, Technical Medical Centre, Faculty of Science and Technology, University of Twente, 7500 AE Enschede, The Netherlands
Tel: (31)534893655
E-mail: k.broersen@utwente.nl

†Present address
C2N Diagnostics, Center for Emerging Technologies, 4041 Forest Park Ave, St. Louis, MO, 63108, USA

(Applied 6 March 2019, revised 19 April 2019, accepted 29 April 2019, available online 27 May 2019)
doi:10.1002/1873-3468.13428

Edited by Sandro Sonnino

Lipids require specialized carriers that transport them through the body, known as apolipoproteins. Apolipoproteins facilitate lipid solubilization and serve as ligands for lipoprotein receptors that mediate cellular lipid uptake and play a role in cell signaling [1]. Apolipoprotein E (ApoE) is one of the most studied members of this protein family, as the APOE genotype has been linked to several neurological disorders, with a strong association with Alzheimer’s disease (AD) [2,3]. ApoE is produced in abundance in the human brain by astrocytes, in less extent by macrophages and stressed neurons, and is the principal lipid transporter in the cerebrospinal fluid [4].

ApoE exists as three isoforms: ApoE2, ApoE3, and ApoE4 [5]. The APOE ε4 allele is the most important genetic risk factor for development of late-onset AD. People carrying one or two copies of the APOE ε4 allele have respectively about 3- and 12-fold more risk

Keywords: aggregation; Alzheimer’s disease; apolipoprotein E; high-density lipoprotein; isoform; lipidation

Abbreviations
(V)LDL, (very) low-density lipoprotein; AD, Alzheimer’s disease; ApoE, apolipoprotein E; Aβ, amyloid-beta peptide; CD, circular dichroism; CSF, cerebrospinal fluid; DLS, dynamic light scattering; FFF-MALS, field flow fractionation multiangle light scattering; HDL, high-density lipoprotein; MRE, mean residue ellipticity; NRMSD, normalized root mean square deviation; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; SDS/PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TEM, transmission electron microscopy; UV, ultraviolet.

1144
of acquiring AD than non-APOE ε4 carriers [6]. In contrast, the APOE ε2 allele is protective [7]. ApoE was initially found to colocalize with plaques containing the amyloid-beta (Aβ) peptide in AD brains [8]. Substantial evidence exists that ApoE contributes to AD pathogenesis by modulating Aβ aggregation and clearance, and by regulating brain lipid metabolism and synaptic functioning through ApoE receptors such as those of the low-density lipoprotein (LDL) receptor family [9–12]. Proposed Aβ-independent roles for ApoE4 in AD include generation of neurotoxic ApoE fragments, impairment of mitochondrial function, and disruption of the cytoskeleton through stimulation of tau phosphorylation [13].

Although the ApoE isoforms only differ by their amino acid compositions at positions 112 and 158 [14], these changes have profound effects on the structure and lipoprotein-binding preferences of the isoforms [15,16]. ApoE consists of two structural domains linked by a flexible hinge region. Although the N- and C-terminal domains interact in ApoE4, this interaction does not occur to the same extent in ApoE2 and ApoE3 [17]. The N-terminal receptor-binding domain is an extended four-helix bundle and is responsible for binding to the LDL receptor. The C-terminal domain of ApoE comprises several amphipathic α-helices and contains the lipid-binding region that is capable of binding different types of lipids (e.g., cholesterol, phospholipids, fatty acids) and lipoproteins, including LDLs, very low-density lipoproteins (VLDLs), and high-density lipoproteins (HDLs). ApoE in the human brain is mainly synthesized by and secreted from astrocytes to generate ApoE-containing HDL-like particles. It has been suggested that astrocyte-secreted HDL particles are discoidal in shape, but the conformation adopted by ApoE in the lipid complexes remains controversial [16].

The mechanistic link between ApoE and AD has been the subject of numerous studies and debates, but it has become clear that the lipidation status of ApoE plays an important role. For the most part, biologically active ApoE is associated with lipids [18] and the ApoE lipidation status has been reported to impact Aβ metabolism, that is, Aβ aggregation and deposition [19–22], and clearance [23–26]. For example, enhanced expression of lipidated ApoE in AD mouse models, through activation of liver X receptors or through overexpression of the ATP-binding cassette A that is responsible for ApoE lipidation, stimulates Aβ clearance [23,27]. Therefore, modulators of ApoE secretion and lipidation are being explored as potential drugs for AD therapy [22,28,29].

Studying ApoE behavior in its lipid-free and lipid-bound state is thus of great importance to enhance our understanding of its functioning in the context of AD pathology. In this study, we therefore produced all three ApoE isoforms in their lipilated and nonlipidated forms, and systematically characterized and compared them by a range of biophysical techniques. The lipidation procedure was carefully selected to mimic in vivo discoidal HDL-like ApoE particles with a physiological lipid composition consisting of phospholipid and unesterified cholesterol [30–32]. Our results confirm the previously reported tendency of lipid-free ApoE to self-assemble in solution [33–36] and provide experimental evidence that lipidation protects ApoE from aggregation.

Materials and methods

Preparation of HDL-like ApoE particles

Preparation of reconstituted ApoE

Lyophilized recombinant human ApoE (Leinco Technologies, Inc., St Louis, MO, USA) was resuspended to a concentration of 1 mg·mL⁻¹ in Dulbecco’s phosphate-buffered saline (DPBS, Thermo Fisher Scientific, Landsmeer, The Netherlands) pH 7.4 containing 0.05 mM dithiothreitol.

Liposome preparation

1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, Avanti Lipids) and unesterified cholesterol (Avanti Polar Lipids) were mixed in a glass vial at a molar ratio of 90 : 5 and dried under a constant nitrogen gas stream. This ratio was selected to mimic the physiological lipid composition of HDL-like ApoE particles [30,31]. Lipids were resuspended in PBS at a concentration of 5 μg lipids·μL⁻¹ PBS. The solution was mixed thoroughly in a vortex mixer and intermittently for 5–10 min (with 1–2 min intervals) to generate liposomes. Complete hydration of liposomes was accomplished by incubating the solution at room temperature for 30 min and occasional vortex mixing.

ApoE lipidation

Lipids can be added directly to ApoE but lipidated particles will be more homogeneous when using the sodium cholate dialysis method [32,37,38]. Therefore, sodium cholate (50 mg·mL⁻¹, Sigma-Aldrich, St. Louis, MO, USA) was slowly titrated into the liposome solution (2–3 volumes of sodium cholate for 1 volume of lipids). The solution turbidity cleared after 5 min of gentle vortex mixing (1 min interval) and the preparation was kept at room temperature for 30–60 min. Reconstituted ApoE was then added to the liposome preparation (ApoE : POPC : cholesterol, molar ratio of 1 : 90 : 5) and mixed gently for 5–10 min (1–2 min

FEBS Letters 593 (2019) 1144–1153 © 2019 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
interval). The solution was kept at room temperature for 1 h and dialyzed (10 kDa cutoff membrane) against PBS for 4 h at room temperature (to promote removal of detergents), followed by 60–72 h at 4 °C. After dialysis, samples were analyzed by gel filtration chromatography (Superdex 200 10/300 GL) and nondenaturing (native) polyacrylamide gel electrophoresis (PAGE). ApoE concentrations were determined by absorbance measurements at 280 nm using an extinction coefficient of 44 460 M⁻¹ cm⁻¹ [39]. Samples were diluted in PBS to 0.1 mg·mL⁻¹ prior to further analysis. All lipoprotein samples were prepared using the same lipid–cholesterol suspension and the procedure was performed in parallel. Samples were stored at 4 °C.

TEM imaging of lipid-free and lipid-bound ApoE

A staining procedure was adapted to assess the formation of HDL-like ApoE particles with TEM [40]. Briefly, carbon-coated Formvar 400-mesh copper grids (AgarScientific, Stansted, UK) were glow discharged prior to sample application. Lipidated ApoE (2 µL of a 0.1 mg·mL⁻¹ sample) was spotted and incubated on the grids for 2 min at room temperature. The grids were subsequently blotted, washed (3 × 2 s, in ultrapure water), and stained with 1% (w/v) uranyl acetate (2 × 2 min). For imaging of lipid-free ApoE, samples were spotted and incubated on grids for 30 s, blotted, washed (1 × 5 s), and stained with 1% uranyl acetate (1 × 30 s). Samples were studied with a JEM-1400 microscope (JEOL Ltd., Tokyo, Japan) at 80 kV. Images are representative of at least three independently prepared samples.

Native PAGE

Lipoprotein particle formation was assessed by native PAGE. Equal amounts of ApoE isoforms (3 µg) were mixed with Novex® Tris-Glycine Native Sample Buffer (1 : 1) to obtain a final volume of 15 µL, and loaded on a 4–20% Tris-glycine gel (Invitrogen). The gel was run at 100 V for 16 h at 4 °C. Sample migration was assessed using the NativeMark™ Unstained protein standard (Life Technologies).

FFF-MALS

For each fractionation, a volume of 10 µL ApoE (0.1 mg·mL⁻¹) was injected in an Eclipse asymmetrical flow field flow fractionation (FFF) system (Wyatt Technology, Santa Barbara, CA, USA), and the flow rate out of the channel was maintained at 1 mL·min⁻¹. Fractionated samples were analyzed with multiangle light scattering (MALS) using the DAWN HELEOS system (Wyatt Technology), an ultraviolet (UV) detector, and an Optilab rEX refractive index detector (Wyatt Technology) connected to the Eclipse system. The MALS system was equipped with a laser operating at 658 nm and measurements were taken at 14.4°, 25.9°, 34.8°, 42.8°, 51.5°, 60.0°, 69.3°, 79.7°, 90.0°, 100.3°, 110.7°, 121.2°, 132.2°, 142.5°, 152.5°, and 163.3°, with reference to the axis of the incident beam. astrA v software (version 5.3.4.14) (Wyatt Technology, Santa Barbara, CA, USA) was used for data acquisition and correction for interdetector delay and band broadening.

DLS

Lipid-free and lipid-bound ApoE (0.1 mg·mL⁻¹ in PBS) were analyzed using dynamic light scattering (DLS). DLS experiments were conducted with a DynaPro DLS plate reader (Wyatt Technology) at 25 °C and at a scattering angle of 158°. Data were analyzed using Dynamics® software (Wyatt Technology) and represent the averages of 15 acquisitions (10 s per acquisition).

CD

ApoE isoforms (0.1 mg·mL⁻¹ in PBS) in the absence and presence of lipids were placed in a quartz cuvette with an optical path of 0.1 cm. Far-UV circular dichroism (CD) spectra were recorded in a Jasco J-715 spectropolarimeter (Jasco, Tokyo, Japan) at 25 °C. The wavelength range was set from 260 to 190 nm with 0.2-nm resolution, 8.0-s response time, and 1.0-nm bandwidth. Data were collected as averages of eight scans at a scanning speed of 50 nm·min⁻¹. Spectra were corrected by subtracting the buffer baseline. Measurements were performed as independent duplicates. Data are presented as the mean residue ellipticity (MRE, in deg cm²·dmol⁻¹). Secondary structure content was estimated using cdstr software and the normalized root mean square deviation (NRMSD) is displayed as a measure of correspondence between the experimental and calculated reference spectra [41,42].

Intrinsic tryptophan fluorescence

Emission fluorescence spectra of lipidated and nonlipidated ApoE isoforms (0.1 mg·mL⁻¹ in PBS) were measured using a LS 55 spectrometer (PerkinElmer, Waltham, MA, USA) at 25 °C. The excitation wavelength was set to 280 nm (5 nm bandwidth) and the emission intensity was scanned from 300 to 450 nm (5 nm bandwidth) at a scan speed of 100 nm·min⁻¹. Spectra were corrected for buffer and represent averages of eight scans. Measurements were performed as independent duplicates.

Results

Astrocyte-secreted ApoE in the brain is predominantly associated with cholesterol and phospholipid-rich HDL-like complexes [30,31]. Therefore, HDL-like
ApoE particles were prepared using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and unesterified cholesterol, in a 1 : 90 : 5 molar ratio (ApoE : POPC : cholesterol), using the sodium cholate dialysis method described previously [38]. The lipiddation procedure was assessed by transmission electron microscopy (TEM) and revealed discoidal lipiddated ApoE particles (Fig. 1).

The sodium cholate procedure resulted in a heterogeneous population of lipid-bound ApoE particles, as shown by field flow fractionation multangle light scattering (FFF-MALS) analysis that detected three fractions with different retention times (Fig. 2). FFF is a high-resolution separation technique that consists of a velocity gradient inside a channel that separates particles based on their size. Smaller particles will be more rapidly transported through the channel than larger ones and will elute first, as opposed to size-exclusion chromatography. The heterogeneity detected for lipidated ApoE particles is consistent with previous studies reporting different sizes for ApoE-containing lipoproteins secreted by astrocytes from transgenic mice expressing human ApoE, and in cerebrospinal fluid (CSF) of human subjects [31,43,44].

Next, ApoE isoforms in their lipid-free and lipid-bound state were characterized using FFF-MALS, native polyacrylamide gel electrophoresis (PAGE), and dynamic light scattering (DLS). The first particles to elute from the FFF channel were the HDL-like ApoE particles, and not the lipid-free ApoE isoforms, as detected by differential refractive index analysis (Fig. 2A), MALS (Fig. 2B), and UV absorbance (Fig. 2C). Although lipid-free ApoE was eluted around 15 min, lipidated ApoE particles displayed shorter retention times, that is, between 12 and 14 min. This result indicates that the size of lipidated ApoE, and specifically the hydrodynamic radius, is smaller than that of lipid-free ApoE. Accordingly, native PAGE revealed that lipid-bound ApoE migrated further in the 4–20% Tris-glycine gel than lipid-free ApoE (Fig. 3A). Moreover, estimations of the hydrodynamic radii by DLS confirmed that lipiddated ApoE, regardless of the ApoE isoform, was smaller than lipid-free ApoE (Fig. 3B). Together, these results suggest that lipid-free ApoE has the tendency to aggregate in solution at a concentration of 0.1 mg·mL⁻¹, whereas lipiddation is capable of impeding this behavior. This tendency is isoform dependent, with the most pronounced aggregation for ApoE4, followed by ApoE3 and ApoE2 (Fig. 3).

The aggregation of lipid-free ApoE4 was visualized by TEM and revealed amorphous aggregates (Fig. 4).

To assess the effect of lipiddation on secondary structure content of ApoE, circular dichroism (CD) measurements were performed. Lipid-free as well as lipid-bound ApoE displayed a predominant α-helical structural signature, characterized by two minima around 208 and 222 nm (Fig. 5A). Lipid-free and lipiddated ApoE displayed approximately 60% α-helicity (Fig. 5B), which corresponds to values reported previously [45]. The mean residue ellipticity was, however, slightly increased in the lipiddated ApoE state with a small gain of α-helicity and loss of β-sheet structure (Fig. 5B). However, taken into account an approximate error of 5% in the measurements, the overall effect of lipiddation on the secondary structure of ApoE was minor.

In contrast, more pronounced differences could be observed in terms of tertiary structure, when lipid-free and lipid-bound ApoE were compared by their intrinsic Trp fluorescence. ApoE has seven Trp residues: four are located in the N-terminal domain and three are situated in the C-terminal lipid-binding domain. ApoE particles displayed a marked blue shift in their fluorescence maximum upon lipiddation (Fig. 6). We attribute this blue shift to tertiary structural alterations in the vicinity of the Trp residues resulting in an increased hydrophobic environment.
Fig. 2. The heterogeneous composition of HDL-like ApoE particles. Lipid-free and HDL-like ApoE particles (0.1 mg/mL in PBS) were separated by FFF and their composition was compared by their (A) differential refractive index, (B) intensity of differential light scattering, and (C) UV absorbance at 215 nm. Obtained spectra are representative of two independently prepared ApoE isoform samples.

Fig. 3. Lipidation impedes aggregation of ApoE. Migration patterns and size distributions of lipid-free and HDL-like ApoE particles (0.1 mg/mL in PBS) were obtained by native PAGE and DLS, respectively. (A) Lipidated ApoE migrates further in a 4–20% Tris-glycine gel compared to lipid-free ApoE (M: NativeMarkTM Unstained protein standard). (B) The hydrodynamic radius of lipidated ApoE is smaller than that of lipid-free ApoE. Obtained data are representative of two independently prepared ApoE isoform samples.
ApoE has been reported to self-assemble [33–36] and the hypothesis has been raised that the amphipathic α-helical structure of ApoE is stabilized upon lipid binding, which may protect it from amyloidogenic folding pathways [36]. We provide experimental evidence that lipidation indeed impedes aggregation of ApoE, by comparing lipid-free ApoE and HDL-like discoidal ApoE particles of all three ApoE isoforms using a biophysical approach.

Our results show that lipid-free ApoE has the tendency to self-assemble, with ApoE4 having the highest aggregation propensity, followed by ApoE3 and ApoE2 (Figs 2–4). This is in accordance with previous observations that provide evidence that ApoE oligomerizes through a monomer–dimer–tetramer association process [34], and can aggregate further from tetramers to higher molecular weight aggregates [33,35]. These aggregates displayed an α-helical structure, in accordance with our results (Fig. 5) [36]. Moreover, the ApoE aggregation rate was previously shown to be isoform dependent (ApoE4 > ApoE3 > ApoE2), which was attributed to differences in conformational stability of the ApoE N-terminal region, with a decreased stability resulting in a higher aggregation rate [36]. Not only ApoE but also other apolipoproteins including ApoA-I, ApoA-II, and ApoB100 display low conformational stability and have the tendency to self-assemble [46].

Despite the importance of the stability of the N terminus, several studies have appointed the C terminus as the main determinant of ApoE self-assembly [35,47–50]. The C terminus of ApoE comprises amphipathic α-helices and exposes a large, hydrophobic surface [17]. As the lipid-binding region of ApoE is situated in the C-terminal region of ApoE, it was hypothesized that there might be a link between ApoE self-assembly and its lipid-binding properties [51,52]. Accordingly, we provide experimental evidence that
lipidation impedes ApoE self-assembly into amorphous aggregates, as ApoE bound to lipids is smaller than when alone in solution, based on its hydrodynamic radius and migration properties (Figs 2–4). Lipidation has minor effects on the secondary structure of ApoE, with the main contribution still arising from α-helices (Fig. 5), but elicits tertiary structural alterations in the vicinity of Trp residues (Fig. 6). This observation is consistent with the general consensus that ApoE undergoes a lipid binding-induced conformational rearrangement [16]. It has been suggested that lipidation might stabilize the amphipathic α-helical structure of ApoE and protect it against aggregation [36]. This is not a property solely applicable to ApoE but also to other apolipoproteins that contain a large proportion of amphipathic α-helices and display low conformational stability in the absence of lipids [46]. It is conceivable that variations in lipid composition may influence the observations made, as it has been shown that distinct discoidal ApoE lipid complexes are formed when varying POPC and cholesterol levels [53]. Further studies are required to establish the impact of levels and type of surface and core lipids on aggregation of ApoE.

Although ApoE mostly occurs in its lipid-bound form in plasma and CSF, there are lipid-poor reservoirs and conditions that are vulnerable to aggregation (e.g., ApoE synthesized by macrophages and neurons in stress conditions) [36]. Therefore, the higher propensity of lipid-free ApoE4 in solution to aggregate compared to other ApoE isoforms as shown by our data, and its ability to form aggregates that are toxic to neuronal cells [36], might underlie its association with AD.

In conclusion, we report that lipid-free ApoE in solution has the tendency to aggregate in vitro in an isoform-dependent manner (ApoE4 > ApoE3 > ApoE2) under near-physiological conditions and that aggregation is impeded by lipidation of ApoE. As ApoE4 aggregates have been demonstrated to be toxic to neuronal cells, these findings might explain the higher AD risk associated with ApoE4 in comparison with other ApoE isoforms.

Acknowledgement
The authors thank David Holtzman for discussions.

Author contributions
The manuscript was written through contributions of all authors. KB and NvN conceived and supervised the study; KB, NvN, and PV designed experiments, EH, KB, and PV performed experiments, PV provided new tools, EH, NvN, KB, and PV analyzed data. All authors have given approval to the final version of the manuscript.

Funding
This work was supported by an FWO doctoral fellowship (EH), the VIB and the Flemish Hercules
Foundation (NvN), Internationale Stichting Alzheimer Onderzoek (ISAO) (KB), an FWO Odysseus II award (KB) and a UTWIST fellowship (KB).

References

1 Dieckmann M, Dietrich MF and Herz J (2010) Lipoprotein receptors—an evolutionarily ancient multifunctional receptor family. *Biol Chem* **391**, 1341–1363.

2 Mahley RW, Weisgraber KH and Huang Y (2009) Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer’s disease to AIDS. *J Lipid Res* **50**(Suppl.), S183–S188.

3 Vergheze PB, Castellano JM and Holtzman DM (2011) Apolipoprotein E in Alzheimer’s disease and other neurological disorders. *Lancet Neurol* **10**, 241–252.

4 Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* **240**, 622–630.

5 Zannis VI and Breslow JL (1981) Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. *Biochemistry* **20**, 1033–1041.

6 Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild G, Salvesen S and Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci USA* **90**, 1977–1981.

7 Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N and van Duijn CM (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* **278**, 1349–1356.

8 Namba Y, Tomonaga M, Kawasaki H, Otomo E and Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. *Brain Res* **54**, 163–166.

9 Mahley RW, Weisgraber KH and Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. *Proc Natl Acad Sci USA* **103**, 5644–5651.

10 Bu G (2009) Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci* **10**, 333–344.

11 Iurescia S, Fioretti D, Mangialasche F and Rinaldi M (2010) The pathological cross talk between apolipoprotein E and amyloid-beta peptide in Alzheimer’s disease: emerging gene-based therapeutic approaches. *J Alzheimers Dis* **21**, 35–48.

12 Liu CC, Kanekiyo T, Xu H and Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol* **9**, 106–118.

13 Huang Y (2010) Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer’s disease. *Trends Mol Med* **16**, 287–294.

14 Weisgraber KH, Rall SC and Mahley RW (1981) Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. *J Biol Chem* **256**, 9077–9083.

15 Zhong N and Weisgraber KH (2009) Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. *J Biol Chem* **284**, 6027–6031.

16 Hauser PS, Narayanawami V and Ryan RO (2011) Apolipoprotein E: from lipid transport to neurobiology. *Proc Lipid Res* **50**, 62–74.

17 Hatters DM, Peters-Libeu CA and Weisgraber KH (2006) Apolipoprotein E structure: insights into function. *Trends Biochem Sci* **31**, 445–454.

18 Innerarity TL, Pitas RE and Mahley RW (1979) Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. *J Biol Chem* **254**, 4186–4190.

19 Carter DB (2005) The interaction of amyloid-beta with ApoE. *Subcell Biochem* **38**, 255–272.

20 Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A et al. (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer’s amyloid beta peptides. *Biochem J* **348**(Pt 2), 359–365.

21 Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW and Carter DB (2005) Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. *Chem Phys Lipids* **137**, 52–61.

22 Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ et al. (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. *Science* **335**, 1503–1506.

23 Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zecler N, Mann K, Lamb B, Willson TM, Collins JL et al. (2008) ApoE promotes the proteolytic degradation of Abeta. *Neuron* **58**, 681–693.

24 Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM and Zlokovic BV (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. *J Clin Invest* **118**, 4002–4013.

25 Wildsmith KR, Holley M, Savage JC, Skerrett R and Landreth GE (2013) Evidence for impaired amyloid beta clearance in Alzheimer’s disease. *Alzheimers Res Ther* **5**, 33.
Lipidation-mediated prevention of apoE aggregation

E. Hubin et al.

26 Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM and Zlokovic BV (2018) Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-b42 by LRPI-dependent apolipoprotein E isoform-specific mechanism. *Mol Neurodegener* **13**, 57.

27 Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington BL, Bales KR *et al.* (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. *J Clin Invest* **118**, 671–682.

28 Yu JT, Tan L and Hardy J (2014) Apolipoprotein E in Alzheimer’s disease: an update. *Annu Rev Neurosci* **37**, 79–100.

29 Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J *et al.* (2014) Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. *J Neurosci* **34**, 7281–7292.

30 LaDu MJ, Gilligan SM, Lukenes JR, Cabana VG, Reardon CA, Van Eldik LJ and Holtzman DM (1998) Nascent astrocyte particles differ from lipoproteins in CSF. *J Neurochem* **70**, 2070–2081.

31 DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han X and Holtzman DM (2001) Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. *Neurochem Int* **39**, 415–425.

32 Vergheze PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C and Holtzman DM (2013) ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. *Proc Natl Acad Sci USA* **110**, E1807–E1816.

33 Perugini MA, Schuck P and Howlett GJ (2000) Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid. *J Biol Chem* **275**, 36758–36765.

34 Garai K and Frieden C (2010) The association–dissociation behavior of the ApoE proteins: kinetic and equilibrium studies. *Biochemistry* **49**, 9533–9541.

35 Chou CY, Lin YL, Huang YC, Sheu SY, Lin TH, Tsay HJ, Chang GG and Shiao MS (2005) Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution. *Biophys J* **88**, 455–466.

36 Hatters DM, Zhong N, Rutenber E and Weisgraber KH (2006) Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. *J Mol Biol* **361**, 932–944.

37 Matz CE and Jonas A (1982) Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. *J Biol Chem* **257**, 4535–4540.

38 Jonas A, Sweeney SA and Herbert PN (1984) Discoidal complexes of A and C apolipoprotein with lipids and their reactions with lecithin: cholesterol acyltransferase. *J Biol Chem* **259**, 6369–6375.

39 Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD and Hochstrasser DF (1999) Protein identification and analysis tools in the ExPASy server. *Methods Mol Biol* **112**, 531–552.

40 Zhang L, Song J, Newhouse Y, Zhang S, Weisgraber KH and Ren G (2010) An optimized negative-staining protocol of electron microscopy for apoE4 POPC lipoprotein. *J Lipid Res* **51**, 1228–1236.

41 Srerama N and Woody RW (2000) Estimation of protein secondary structure from circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSSTR methods with an expanded reference set. *Anal Biochem* **287**, 252–260.

42 Whitmore L and Wallace BA (2008) Protein secondary structure analyses from circular dichroism spectroscopy: methods and reference databases. *Biopolymers* **89**, 392–400.

43 Fagan AM, Holtzman DM, Munson G, Mathur T, Schneider D, Chang LK, Getz GS, Reardon CA, Lukens J, Shah JA *et al.* (1999) Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. *J Biol Chem* **274**, 30001–30007.

44 Yamauchi K, Tozuka M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y and Katsuyma T (1999) Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. *Clin Chem* **45**, 497–504.

45 Morrow JA, Segall ML, Lund-Katz S, Phillips MC, Knapp M, Rupp B and Weisgraber KH (2000) Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain. *Biochemistry* **39**, 11657–11666.

46 Hatters DM and Howlett GJ (2002) The structural basis for amyloid formation by plasma apolipoproteins: a review. *Eur Biophys J* **31**, 2–8.

47 Aggerbeck LP, Wetterau JR, Weisgraber KH, Wu CS and Lindgren FT (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. *J Biol Chem* **263**, 6249–6258.

48 Westerlund JA and Weisgraber KH (1993) Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. *J Biol Chem* **268**, 15745–15750.

49 Fan D, Li Q, Korando L, Jerome WG and Wang J (2004) A monomeric human apolipoprotein E carboxyl-terminal domain. *Biochemistry* **43**, 5055–5064.

50 Wisniewski T, Lalowski M, Golabek A, Vogel T and Frangione B (1995) Is Alzheimer’s disease an apolipoprotein E amyloidosis? *Lancet* **345**, 956–958.
51 Zhang Y, Vasudevan S, Sojitra R, Zhao W, Cui C, Xu C, Fan D, Newhouse Y, Balestra R, Jerome WG et al. (2007) A monomeric, biologically active, full-length human apolipoprotein E. *Biochemistry* **46**, 10722–10732.

52 Garai K, Baban B and Frieden C (2011) Dissociation of apolipoprotein E oligomers to monomer is required for high-affinity binding to phospholipid vesicles. *Biochemistry* **50**, 2550–2558.

53 Gong EL, Nichols AV, Weisgraber KH, Forte TM, Shore VG and Blanche PJ (1989) Discoidal complexes containing apolipoprotein E and their transformation by lecithin-cholesterol acyltransferase. *Biochim Biophys Acta* **1006**, 317–328.